Rindopepimut
Rindopepimut (pronounced rin-doh-pep-i-mut) is a vaccine developed for the treatment of glioblastoma, a type of brain tumor.
Etymology
The name "Rindopepimut" is derived from the scientific nomenclature used to describe its function. "Rindo" is short for "rindopepimut", which refers to the specific antigen the vaccine targets. "Pepimut" is a combination of "peptide" and "mutant", indicating that the vaccine is designed to target a mutant peptide.
Description
Rindopepimut is an experimental vaccine that was developed to target the epidermal growth factor receptor variant III (EGFRvIII), a mutation found in about 30% of glioblastoma cases. The vaccine is designed to stimulate the body's immune system to attack cells expressing EGFRvIII, thereby inhibiting tumor growth.
Clinical Trials
Rindopepimut has undergone several clinical trials to evaluate its safety and efficacy. The most notable of these was the ACT IV trial, which unfortunately did not meet its primary endpoint of improving overall survival in patients with newly diagnosed glioblastoma.
Related Terms
External links
- Medical encyclopedia article on Rindopepimut
- Wikipedia's article - Rindopepimut
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski